When asked about all the deaths other than those in relation to Amiodarone being reported, there was no response. A letter to the FDA asking them to inform the public of these problems resulted in a response that they informed the public about deaths resulting from an interaction with the drug Amiodarone, which causes a slowing of the heart. More recently there are numerous reports of very aggressive cancers developing and patients dying within weeks after taking Harvoni. Some of those to include, but are not limited to, long-term problems of tinnitus, severe neuropathy, joint pain, muscle pain, constant headache, chronic fatigue, heart issues, lung issues, and vision problems. One can go on any Hepatitis C internet forum and read statements from patients taking or who have taken the drug of their multiple problems above and beyond those indicated by Gilead. The FDA, in their own reporting system of adverse events (FAERS), show dozens of reports of sudden death, respiratory failure, renal failure, cardiac failure, hepatic failure and as well as hundreds of reports of a myriad of other problems, yet the public hears none of this and doctors are denying problems. The FDA approved the drug under breakthrough therapy designation, which is intended to expedite the development and review of drugs for serious conditions. Ledipasvir plus sofosbuvir is the first combination tablet approved for the treatment of patients with chronic HCV genotype 1 infection, as well as, the first approved regimen that does not require the use of interferon or ribavirin. On October 10, 2014, the FDA approved the fixed-dose combination capsule of ledipasvir plus sofosbuvir (Harvoni Gilead Sciences) for the treatment of patients with chronic HCV genotype 1 infection. It is estimated that 150 million people world-wide may have the Hepatitis C Virus.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |